HeXun Biosciences (6986) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 和迅

HeXun Biosciences (6986) reported revenue of NT$10.6 million for Oct 2026, -59.8% year on year and -36.4% from the previous month. Revenue for Jan–Oct 2026 was NT$230.5 million (-1.7% year on year).

In Oct 2026, it ranked No. 135 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$26.4 million24/10Nov 2024 NT$27 millionDec 2024 NT$32.1 millionJan 2025 NT$12.5 millionFeb 2025 NT$17.2 million25/02Mar 2025 NT$21.1 millionApr 2025 NT$31.4 millionMay 2025 NT$42.5 millionJun 2025 NT$26.8 million25/06Jul 2025 NT$14.5 millionAug 2025 NT$20.4 millionSep 2025 NT$21.7 millionOct 2025 NT$26.5 million25/10Nov 2025 NT$25 millionDec 2025 NT$33.8 millionJan 2026 NT$15.4 millionFeb 2026 NT$19.1 million26/02Mar 2026 NT$38.1 millionApr 2026 NT$16.7 millionMay 2026 NT$46.8 millionJun 2026 NT$30.4 million26/06Jul 2026 NT$15.3 millionAug 2026 NT$21.4 millionSep 2026 NT$16.7 millionOct 2026 NT$10.6 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$10.6 million-59.8%-36.4%
Sep 2026NT$16.7 million-22.7%-21.8%
Aug 2026NT$21.4 million+4.8%+39.9%
Jul 2026NT$15.3 million+5.8%-49.6%
Jun 2026NT$30.4 million+13.4%-35.1%
May 2026NT$46.8 million+10.1%+180.0%
Apr 2026NT$16.7 million-46.8%-56.1%
Mar 2026NT$38.1 million+80.8%+99.6%
Feb 2026NT$19.1 million+10.9%+24.3%
Jan 2026NT$15.4 million+23.1%-54.6%
Dec 2025NT$33.8 million+5.4%+35.1%
Nov 2025NT$25 million-7.3%-5.5%
Oct 2025NT$26.5 million+0.3%+22.1%
Sep 2025NT$21.7 million+1.8%+6.0%
Aug 2025NT$20.4 million-27.3%+41.2%
Jul 2025NT$14.5 million-30.7%-46.0%
Jun 2025NT$26.8 million-52.1%-37.0%
May 2025NT$42.5 million+7.4%+35.4%
Apr 2025NT$31.4 million+72.3%+49.0%
Mar 2025NT$21.1 million+210.2%+22.4%
Feb 2025NT$17.2 million+628.0%+38.1%
Jan 2025NT$12.5 million+19.8%-61.1%
Dec 2024NT$32.1 million-18.1%+18.9%
Nov 2024NT$27 million+34.9%+2.3%
Oct 2024NT$26.4 million+129.5%+23.9%

Jan–Oct 2026 cumulative: NT$230.5 million (-1.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: HeXun Biosciences vs PEC / HeXun Biosciences vs Lotus Pharm / HeXun Biosciences vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

因10月份工作日天數較少,使特定專案執行時程遞延,導致收入認列較去年同期減少

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16